cyrilzakka/clinical-trials huggingface dataset:
Evaluating Dashboard-Integrated Pharmacist-Led Education on Improving Sacubitril/Valsartan Adherence in Heart Failure (PharmD ASSIST HFrEF)

The goal of this pragmatic clinical trial is to evaluate whether pharmacist-led education, integrated with interactive visualization dashboards, can enhance medication adherence in patients with heart failure who are prescribed sacubitril/valsartan. The main question it aims to answer is: Can pharmacist-led interactive visualization dashboards improve adherence to sacubitril/valsartan compared to usual care without the dashboard intervention?

Researchers will compare patients receiving pharmacist-led education with interactive dashboards to those receiving standard education, assessing differences in medication adherence and clinical outcomes, among others.

Participants will:

* Complete baseline and follow-up questionnaires on medication adherence and satisfaction with pharmacist-provided services, and others.
* Engage in education sessions led by pharmacists, with or without dashboard integration.

The study outcomes will include medication adherence, and secondary outcomes such as patient satisfaction with pharmacist-provided services, optimized guideline-directed medical therapy score, time to high medication adherence, the calculated proportion of days covered, New York Heart Association functional classification, and the net promoter score used for evaluating recommendation and satisfaction with the dashboard intervention.


Eligibility Criteria:
Inclusion Criteria:

* adults aged 20 or older
* a diagnosis of HFrEF, which is defined by a left ventricular ejection fraction of 40% or less
* currently receiving sacubitril/valsartan at the time of recruitment
* receiving care at the cardiology department or cardiology ward at National Taiwan University Hospital
* referral from the clinicians at National Taiwan University Hospital

Exclusion Criteria:

* unable or unwilling to provide informed consent, adhere to study protocols, or complete required questionnaires in person during three scheduled visits (i.e., 3, 6, 12 months after the baseline measurement)
* having received care at the pharmacist-led HF clinic at National Taiwan University Hospital
BRown Fat Activity Measurement With Infrared imaginG tHermography andThermogenesis - the BRIGHT Study

The whole body calorimeter is sensitive enough to reliably measure cold-induced thermogenesis as a surrogate marker of brown adipose tissue (BAT) activation.

The infrared (IR) energy flux from activated BAT can be accurately imaged and quantified using an IR imaging device, and that this IR energy output may be correlated to the increased energy expenditure quantified by the whole body calorimeter.

The recent rediscovery of functional brown adipose tissue (BAT) in healthy adults has opened up the exciting possibility of manipulating BAT for obesity management, and it is imperative to develop BAT imaging modalities that are non-invasive and safe for repeated use. Given that heat is a specific end-product of uncoupling protein-1 (UCP-1)-mediated BAT, this study examines whether surface body temperature assessed using infrared (IR) thermography can be a non-invasive measure to accurately and precisely predict brown adipose tissue (BAT) activation upon cold stimulation, which involves verifying an semi-automated method for characterizing thermal images. In addition, this study also aims to validate the use of a whole-body calorimeter to pick up changes in energy expenditure upon cold-induced thermogenesis. Lean, healthy male volunteers will be recruited. Thermal imaging of cervical-supraclavicular BAT will be done using an IR camera to assess changes in BAT activation. Blood samples will also be drawn at regular intervals to track changes in serum metabolites upon BAT activation. All in all, this study hopes to provide more supporting evidence that IR thermography is a viable imaging modality that is non-invasive, safe and reproducible of studying BAT activity.

Eligibility Criteria:
Inclusion Criteria:

* Male
* Ethnic Chinese
* Age between 21 to 35 years
* Body Mass Index 18.5 to 22.9
* Normal resting blood pressure \~120/80 mmHg
* Normal fasting blood glucose level \<5.5 mmol/L

Exclusion Criteria:

* Do not train for or partake in competitive sports
* Do not have any major diseases
* Not on any prescribed medication
The Effect of a Wearable Hip Assist Robot on Cardiopulmonary Metabolic Efficiency During Stair Ascent in Elderly Adults

The aim of this study was to identify the assistance effect of the new wearable hip assist robot, gait enhancing mechatronic system (GEMS) developed by Samsung Advanced Institute of Technology (Samsung Electronics Co, Ltd., Korea) during stair ascent by comparing the energy expenditure of elderly adults with and without the GEMS.

Primary objective of this study is to demonstrate the effect of a wearable hip assist robot on cardiopulmonary metabolic efficiency during stair ascent in elderly adults.

Fifteen elderly adults participated in this study. The stair ascent trials were designed to climb stairs from the first basement level to the fourth floor of the Proton Therapy Center, Samsung Medical Center, Korea. The metabolic energy expenditure was measured using a portable cardiopulmonary metabolic system (Cosmed K4b², Rome, Italy) while participants performed randomly assigned two different conditions consecutively:, free ascent without the GEMS (NoGEMS) or robot-assisted ascent with the GEMS (GEMS). Participants rested for 10 minutes between the two trial conditions.

Eligibility Criteria:
Inclusion Criteria:

* Elderly adults who absence of a history of musculoskeletal or central nervous system diseases
* High levels of physical performance (SPPB \> 8)

Exclusion Criteria:

* Elderly adults who absence of the ability to walk independently due to visual field defects, fractures, or severe muscle weakness
* Severe dizziness that might lead to falls
* Cognitive disorders that might be difficult to understand accurately in this study
Video-based Family Therapy for Peripartum Depression in Home Visited Mothers

This pilot study will explore the feasibility and acceptability of implementing a family-based treatment, using HIPAA-compliant video-based communication technology, for adolescents (pregnant and post-delivery) with peripartum depressive symptoms within the context of home visiting.

The purpose of the pilot study is to partner with two Federal Maternal, Infant and Early Childhood Home Visiting (HV) Program sites to implement a family-based treatment for depression, using HIPAA-compliant video-based communication technology, in adolescent mothers (pregnant and post-delivery). This implementation-effectiveness hybrid trial includes depressed adolescent mothers and their adult family members.

It has three aims:

1. Explore the feasibility of integrating the treatment model into two Federal HV Program sites in New Hampshire.
2. Test the acceptability of the treatment model among depressed adolescent mothers and their families.
3. Explore preliminary impacts of the treatment on maternal depressive symptoms and parenting attitudes, family emotion regulation, and family functioning at two months post-intervention.

Eligibility Criteria:
Home Visitor Inclusion Criteria:

1. Willingness to participate in the study;
2. Intention to remain in current job for at least 12 months; and
3. Fluency in English: The training, treatment model, implementation meetings, and supervision sessions will be carried out in English.

Family Inclusion Criteria:

1. Adolescent mothers, ages 13-25, in the first trimester of pregnancy through eighteen months postpartum;
2. Adolescent mothers with Edinburgh Postnatal Depression Scale scores of ≥8;
3. At least one of the adolescent mother's family members ("family member" is defined as a person she is biologically related to, or significant close others/partners with whom she is not biologically related) must be willing and available to participate in eight of the 10 video-based family therapy sessions;
4. Fluency in English: The treatment will be carried out in English; and
5. Consistent internet access (i.e., subscribe to an internet service provider and do not experience weekly disruptions in service) on a cell phone, tablet, or computer equipped with a camera and microphone.

Family Exclusion Criteria:

Adolescent mothers with

1. A current positive screen for problem alcohol use on the CAGE or TWEAK;
2. A current positive screen on the drug abuse items on the home visiting interview;
3. A current positive screen for domestic violence on the Relationship Assessment Tool;
4. Current hallucinations and/or delusions;
5. Current homicidal ideation;
6. Current suicidal ideation;
7. Current severe major depressive episode as measured by the SCID-V Depression Module for those over age 18, or NIMH DISC-Y \& DISC-P Mood Module for those under age 18; and/or
8. Current self-injurious behavior (e.g., cutting arms on a weekly basis). Families with
9. Current Child Protection Service involvement;
10. Current family therapy service involvement; and/or
11. Current or previous Dialectical Behavior Therapy (DBT) treatment.
Ziprasidone And Olanzapine's Outcomes In Mania

The purpose of this study is to compare the efficacy and tolerability of ziprasidone versus olanzapine in the treatment of acute mania. An open label extension will further evaluate the efficacy, safety, and tolerability of ziprasidone compared with olanzapine. Study recruitment was stopped due to difficulty in enrolling the targeted number of patients on July 30, 2007. Subjects that were enrolled at the time completed the study as per protocol. There were no safety concerns involved in the decision to stop enrollment. The Last Subject Last Visit was January 10, 2008.


Eligibility Criteria:
Inclusion Criteria:

* Have a primary diagnosis of Bipolar I Disorder, current episode manic (DSM-IV 296.4x) or mixed (DSM-IV296.6x) as determined by a structured clinical interview (Mini International Neuropsychiatric Interview (MINI)) at screening.
* A minimum score of 20 on the YMRS (Youngs Mania Rating Scale).

Exclusion Criteria:

* Have a diagnosis of learning disability or organic brain syndrome.
* Have a substance-induced psychotic disorder or behavioral disturbance thought to be due to substance abuse.
Extraction of Impacted 3rd Molars, Can Bone Support of the Second Molar be Promoted by a Bio-Oss Graft?

A prospective study examining bilateral 3rd molar extraction, by a split mouth protocol the investigators augment unilaterally and compare periodontal parameters in between.

40 patients will undergo bilateral 3rd molar extractions, in each patient one side would be augmented by a "Bio-Oss" xenograft.

Post operative, periodontal parameters such as pocket depth and mobility will be evaluated and compared.

Eligibility Criteria:
Inclusion Criteria:

* Bilateral impacted 3rd molars.
* Healthy individuals

Exclusion Criteria:

* Smokers
* Alcohol abusers
* Pregnancy
Protocol for Optimizing Colonoscopy Preparation in Patients With Inflammatory Bowel Disease

Clinical trial evaluating efficacy of bowel cleansing solutions in patients with Inflammatory Bowel Disease.

Simple blind, randomized study evaluating efficacy of 1LPEG vs 2L PEG vs 2L sodium picosulfate in bowel cleansing of patients diagnosed of Inflammatory Bowel Disease undergoing diagnostic or follow-up routine colonoscopy.

Eligibility Criteria:
Inclusion Criteria:

* Patients between 18y and 90y
* Patients with a diagnosis of IBD undergoing follow-up or screening colonoscopy

Exclusion Criteria:

* Patients \<18y or \>90y
* Pregnant Women
* Patients with a past history of inadequate bowel cleansing in a colonoscopy performed in the previous 12 months prior to initiation of study
* Patients with a history of bowel resection
* Patients undergoing therapeutic colonoscopy
* Patients unable to understand study protocol
Effects of Fluid Infusion on Postoperative Vomiting in Pediatric Patients Undergoing Otorhinolaryngological Surgery

Otorhinolaryngological surgery is one of the commonly applied procedures surgical treatments of children in the world. Postoperative vomiting (POV) is an important part of the management of pediatric anesthesia in this surgery that is also related with these surgical procedures. Postoperative vomiting is one of the most common complication of this surgery and may cause patients to receiving anesthesia again and stay longer in the hospital.The use of effective fluid therapy might be a safe way to reduce POV. There are many studies of fluid therapy adult patients on the other hands the number of children studies are limited.

The aim of this study was to evaluate the POV effect of intraoperative hydration with 0.9 NaCl solution in children undergoing otorhinolaryngological surgery.

After institutional ethics committee approval and written informed parental consent, ASA physical status I or II, aged 2-14 year, who were undergoing elective day case otorhinolaryngological surgery under general anaesthesia, were screened for eligibility for enrollment in this prospective, randomized, double blind, placebo controlled study.

In the operating room, after routine monitoring, general anaesthesia was induced with %8 sevoflurane in 100% oxygen by a face mask with spontaneous ventilation.

Patients were randomly assigned to one of the two groups. Randomization was carried out using a computer-generated random numbers.

The control group (Group I) received ≤10 ml kg-1 h-1 and the high volüme group ( Group II) received \>30 ml kg-1h-1 of intravenous %0.9 NaCl solution.Before tracheal intubation, all subjects received propofol 2:5mg kg-1, fentanyl 1µg kg-1 and rocuronium 0.6 mg kg-1.

After tracheal intubation, anaesthesia was maintained with 40% mixture of oxygen/nitrous oxide and 2% sevoflurane. The solution appears to be covered via an infusion pump was used. During anaesthesia, all patients received intravenous paracetamol 10 mg kg-1 for postoperative pain .

Following extubation, until the transfer of the patient from the time of the PACU nausea, vomiting or both were recorded..

Retching efforts in the PACU were recorded as nausea evaluated. Both nausea and vomiting were assessed on a four point scale: 0=no nausea/vomit, 1=mild nausea/vomit, patient not requesting metoclopramide, 2=nausea/vomit, patient requesting metoclopramide and 3=nausea/vomit resistant to treatment At the first episode of severely nause and vomiting, or both, a rescue antiemetic consisting of intravenous ondansetron was administered.

Intensity of pain was evaluated using Children's Hospital East Ontario Pain Scale (CHEOPS).

Knowledge collection for posoperative pain to PACU arrival and departure was performed by a postanesthesia care unit (PACU) nurses who blinded to the procedure the amount of fluid therapy.

Eligibility Criteria:
Inclusion Criteria:

* 2-14 years
* ASA I-II

Exclusion Criteria:

* Gastroesafageal reflu
* Premedication antiemetic
Rhythmic Reading Training Compared to 'Abilmente' Method

The purpose of the present study is to compare the effectiveness of Rhythmic Reading Training (RRT), a computer-assisted intervention method that combines sublexical reading exercises with rhythm processing, and that of a multimodal intervention comprising different methodology, called 'Abilmente'. All interventions were delivered for a period ranging 1-2,5 months, in 60 minutes biweekly sessions.


Eligibility Criteria:
Inclusion Criteria:

* having been diagnosed with DD (ICD-10 code: F81.0) on the basis of standard inclusion and exclusion criteria (ICD-10: World Health Organization, 1992) and of the diagnosis procedure followed in the Italian practice

Exclusion Criteria:

* presence of comorbidity with other neuropsychiatric or psychopathological conditions (whereas comorbidity with other learning disabilities were allowed)
* exclusion criteria for the use of tDCS (e.g. epilepsy, pregnancy).
Trial in Elderly With Musculoskeletal Problems Due to Underlying Sarcopenia - Faeces to Unravel Gut and Inflammation Translationally

The overall aim of the TEMPUS-FUGIT study is to assess gut microbiota composition in older persons without sarcopenia and to determine the relationship with and between intestinal and systemic inflammation and with sarcopenia-defining parameters (muscle mass, muscle strength and physical performance). The gut microbiota of older persons without sarcopenia (included in TEMPUS-FUGIT) will be compared with the gut microbiota of older people with sarcopenia, participating in the Exercise and Nutrition for Healthy AgeiNg (ENHANce) study (NCT03649698).


Eligibility Criteria:
Inclusion Criteria:

* Male or female persons without probable, confirmed or severe sarcopenia according to the European Working Group on Sarcopenia in Older People (EWGSOP2): no reduced muscle strength measured by chair stand test or hand grips strength
* 65 years or older
* Community-dwelling elderly or assisted living
* Dutch speaking

Exclusion Criteria:

* Impairments/diseases that affect performance of daily activities
* Persons who are systematically physically active (e.g. routine or organized sports activities) or who followed a physical activity training program (e.g., rehabilitation program) in the last 6 months (systematically = twice or more/week)
* Diagnosis of diabetes mellitus, measured by fasting glucose ≥126 mg/dL or HbA1C ≥ 6.5% at screening or in recent (maximum 3 months old) lab report
* Use of antibiotics in the last 3 months
* Gastrointestinal cancer (active or treated in the last 5 years)
* No freezer at home available

After the screening visit, included persons will be invited for a test visit.
Pyramidal Versus Continuous Training Effects on Fatty Liver

exercise is very important maneuver in the control of elevated liver enzymes in complaint of fatty liver .. the exercise forma are many.. from these exercises, pyramidal training or continues aerobic one.

the total participating subjects of the two groups of this study will be fatty liver subjects (19 subjects in every group). aerobic training on electronic treadmill will be adopted for 60 minutes in one group. In the other group, a pyramidal training will be adopted for nearly 60 minutes (nearly two rounds of 21 minutes of running on electronic treadmill will be separated with 10 minutes of rest between the two rounds. Also, warming (4 minutes before start of pyrimidal trianing) and cooling (4 minutes after pyramidal training) will be done through gentle stretching exercises/activities. the both forms of exercises will be done three times per week. the total study time will be 12 weeks. to be mentioned , the two groups followed low clorie diet

Eligibility Criteria:
Inclusion Criteria:

* fatty liver patients
* obese patients
* all patients will class one obesity

Exclusion Criteria:

* cardiovascular complaint
* metabolic complaints
* othopedic pains in lower limbs
Study on Management Thrombosis in Greek Cancer Patients

Study on Management Thrombosis in Greek cancer patients

The approach that Medical Oncologists encounter the prospect of a coagulation event occurrence in cancer patients.

Eligibility Criteria:
Inclusion Criteria

* All patients diagnosed with histologically confirmed solid tumors that are under anticoagulation therapy, during the study timeline.
* Age ≥ 18 years
* Signed informed consent

Exclusion Criteria

* Initiation of anticoagulation therapy before the initiation of the study in 2016
* Age \<18 years
* No signed informed consent
Non Invasive Brain Stimulation Treatment for CLBP

This trial is designed to preliminary evaluate the efficacy and safety of NIBS system for treatment of chronic low back pain (CLBP) (over 6 months). The trial is of a double blind sham controlled partial crossover design and will involve 2 weekly treatments and evaluations for 6 weeks, with 6 weeks follow-up. The goal of the study is to 1. Asses the CLBP change immediate and long term effect for the trial duration and follow-up. 2. Asses quality of life improvement as measure by sleep quality and questioners. 3. Asses long term neuronal changes or lack thereof in treated and untreated subjects.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 to 80
* CLBP as defined by the European guidelines.
* low back pain first week average NPRS\>4.

Exclusion Criteria:

1. Acute low back pain (duration of less than 6 months) first week average NPRS\> 4
2. Neurological illness causing structural brain damage (e.g. Stroke, TIA)
3. Psychiatric disease other than mood disorders
4. Current chronic use of medications with pro-epileptic properties
5. Known alcohol dependency
6. Use of alcohol within the previous 24 hours
7. History of loss of consciousness
8. Epilepsy or epilepsy in a first degree relative
9. Medical implants
10. Pregnancy
11. Illicit drug use or within the previous month
Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis

This clinical trial studies the use of surveys, blood testing, and fibroscan in screening for liver fibrosis and liver cirrhosis in new or existing patients of the HOPE clinic seeking usual clinical care. Fibroscan is an imaging procedure of the liver which uses a probe like an ultrasound. Information gathered from this study may help researchers learn more about how to prevent or find liver cancer in patients who are currently receiving care at the HOPE clinic. Early detection of liver cancer may improve survival.

PRIMARY OBJECTIVE:

I. To estimate the sensitivity of the modified Center for Disease Control (CDC) hepatitis survey in diagnosing chronic hepatitis B virus (HBV) among HOPE clinic patient.

SECONDARY OBJECTIVES:

I. To estimate the sensitivity of the modified CDC hepatitis survey in identifying chronic active hepatitis C virus (HCV) infection among HOPE clinic patients.

II. To estimate the sensitivity of fibrosis serum biomarkers, non-alcoholic fatty liver disease fibrosis score (NFS), fibrosis-4 index (FIB-4), and fatty liver index (FLI) in detecting fibrosis (fibroscan result \>= F2) among HOPE clinic patients with metabolic conditions.

III. To estimate the sensitivity of the Alcohol Use Disorder Identification Test Alcohol Consumption (AUDIT-C) in identifying fibrosis (fibroscan result \>= F2) among HOPE clinic patients.

IV. To estimate the sensitivity of the AUDIT-10 survey in identifying fibrosis (Fibroscan result \>= F2) among Hope Clinic patients who scored \>= 4 for men or \>= 3 for women on the AUDIT-C.

V. To estimate the specificity and accuracy of each of these risk factor screening tools in HOPE clinic patients.

VI. To estimate the prevalence of fibrosis and cirrhosis risk factors among HOPE clinic patients.

EXPLORATORY OBJECTIVES:

I. To explore factors associated with each fibrosis/cirrhosis risk factor. II. To investigate differential diagnostic accuracy of screening methods by fibrosis severity.

III. To evaluate the diagnostic performance of each dichotomized biomarker (NFS, FIB-4, and FLI) separately and assess biomarker optimal cutpoints for identifying fibrosis in the study population.

OUTLINE:

Patients complete surveys over 10-15 minutes, and undergo blood testing, clinical evaluation, and fibroscan at baseline.

After completion of study, patients are followed up at 3 months.

Eligibility Criteria:
Inclusion Criteria:

* Must be at least 18 years old
* Must be a new or existing patient of the HOPE clinic seeking usual clinical care
* Must be able to speak and read English or a language other than English for which there is a translator available on site at the HOPE clinic

Exclusion Criteria:

* Known pregnancy at time of recruitment. The HOPE clinic will ask the female patients if they are pregnant, will ask the participants for their last menstrual period (LMP), and/or they will use the urine pregnancy test (UPT) results in their electronic medical records